Forian Inc.

Max Wygod is a healthcare executive and investor with years of experience investing, acquiring and divesting public and private growth companies at the intersection of healthcare and information technology. Max leads the investment strategy for Wygod & Co. LLC, a virtual family office dedicated to private and public investments in the healthcare industry. The organization works with a group of successful healthcare managers and investors that have been colleagues and partners with Max’s father, Marty Wygod, over his 50 years in the industry. Marty has successfully led seven public companies, primarily in early stage. The appreciation in value of Marty’s companies to public investors has been over $15 billion. He has worked with their directors and management to provide strategic direction to differentiate them from their competitors and enhance their value in the public markets, culminating with the sale of WebMD to a KKR portfolio company for $2.8 billion.

Previously, Max served as a Vice President of Business Development at WebMD Health, where he participated in facilitating its sale to KKR. A seven-year veteran at WebMD, Max had various business development and operating roles that included, but not limited to, WebMD’s strategic growth objectives through capital allocation, acquisitions, partnerships, joint ventures, commercial relationships, investments and divestitures.

Max received a BA from Duke University and an MBA from The Stern School at New York University.

Adam Dublin is a seasoned entrepreneur and senior executive with extensive strategy, business development, and operating expertise in healthcare information and technology. He is responsible for developing Forian’s strategy, data acquisition, partnership development and acquisitions, and he has over 30 years of experience in creating innovative businesses. Prior to the sale of the company to KKR for $2.8 billion, he was on the executive leadership team of WebMD as Senior Vice President, Strategy and Analytics. In that role, he was responsible for developing the company’s marketing science platform, including the development of one of the world’s largest healthcare customer databases, linking patient, consumer demographic and online behavioral data in a HIPAA-compliant manner.

Previously, he was Vice President, Strategy and Corporate Development for IMS Health, the world’s largest healthcare information provider (now IQVIA). He came to IMS Health from SDI, where he was the Chief Strategy Officer. SDI was the recognized leader in longitudinal patient data prior to its acquisition by IMS health in 2011 for $340 million. His track record at SDI included multiple strategic acquisitions that enabled the company to continuously drive growth, resulting in the company eventually becoming the third-largest pharmaceutical informatics organization in the US. At SDI, he patented encryption and de-identification technologies that enabled the linkage of patient databases to a HIPAA-compliant standard, creating one of the first and largest Real World Evidence (RWE) platforms supporting health economics and outcomes research. Prior to SDI, Adam was Senior Vice President Corporate Key Accounts for NDCHealth, one of the nation’s largest healthcare IT companies and the nation’s second-largest pharmaceutical informatics organization. He had P&L for NDC’s wholesale data businesses, commercializing data assets to multiple industries and creating new lines of business in payer analytics, benefits administration, underwriting, and consumer analytics. Adam was instrumental in the sale of the company’s pharmaceutical informatics business to Wolters Kluwer for $352 million. Prior to NDCHealth, he was one of the founders of Health Market Science, a provider data solutions business specializing in data mining and probabilistic matching technologies that was sold to Edison Ventures for $65 million, and now owned by LexisNexis.

Adam received a BA from the University of Iowa and an MA from Northwestern University.

Andrew brings over 20 years of experience leading data science, technology and strategy teams. Most recently, Andrew helped propel RELX through data and digital transformation in a global capacity, leading data platform, analytics and data science as Vice President, Data and Data Science — Research Products. Previously, Andrew served as IBM Corporate Vice President of Data Platforms and Data Strategy. There, he was responsible for building a best-in-class big data platform connecting consumer touch-points, from impression to revenue. In addition, he also led teams in the implementation of the MarTech/AdTech stack and created AI capabilities around multitouch attribution, content and audience targeting and visibility to performance.

Prior to joining IBM, Andrew was GVP of Marketing Science at WebMD, where he created their research and data analytics platforms, driving digital promotion targeting and strategy, editorial content delivery, client insight, and value measurement. Andrew also led the development and commercialization of predictive models of seasonal epidemiological events (e.g., cold and flu, allergy, flea and ticks, STDs) that are currently being used for programmatic media buying and bio-surveillance tracking. Earlier, Andrew led a consultancy team of advanced analytics experts and statisticians as SVP of Marketing Science at GFK, was a principal data scientist at Unilever, and, early in his career, was lead statistician for a small biotech company, PsychoGenics, on the forefront of utilizing Bayesian statistics for novel compound discovery.

Andrew has a BS in Biological Psychology from Colorado State University, as well as an MS and a completed PhD work in Behavioral Neuroscience at Binghamton University.